Ribavirin (ICN-1229)

Synonyms: NSC-163039, RTCA, Tribavirin

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.

Ribavirin (ICN-1229) Chemical Structure

Ribavirin (ICN-1229) Chemical Structure

CAS: 36791-04-5

Selleck's Ribavirin (ICN-1229) has been cited by 21 Publications

3 Customer Reviews

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Ribavirin (ICN-1229) Related Products

Choose Selective Antiviral Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
E6SM cell lines Function assay Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines, EC50=0.005 μM 11495586
MDCK cells Function assay 3 days Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis, EC50=0.094 μM 23117173
mouse L1210 cells Function assay 20-60 mins Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM 22555152
human CEM cells Function assay 20-60 mins Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM 22555152
BHK21 cell line Function assay Inhibition of West Nile virus VLP replicon in BHK21 cell line, EC50=1.1 μM 16539402
HeLa cell Function assay Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines, EC50=1.5 μM 11495586
MDCK cells Function assay 36 h Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs, IC50=1.9 μM 22341943
MDBK cells Function assay 2 days Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR534 infected in MDBK cells assessed as reduction of viral cytopathic effect after 2 days bt MTS assay, EC50=4.6 μM 22944333
african green monkey Vero cells Function assay 5 days Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay, EC50=7 μM 20359898
HEL cells Function assay 2-3 days Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50=10 μM 20034711
HEK293 cells Function assay 24 h Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay, EC50=15 μM 24313730
human BE(2)-C cells Function assay 18-20 h Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay, IC50=16 μM 24151954
human HuH7-J20 cells Function assay Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs, EC50=30.4 μM 26428870
human MT4 cells Cytotoxic assay 96 h Cytotoxicity against human MT4 cells after 96 hrs by MTT assay, CC50=31 μM 19482481
human HuH7 cells Cytotoxic assay 3 days Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay, CC50=32 μM 22100256
human KB cells Function assay 72 h Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control 722730
human KB cells Function assay 1-1000 μg/ml 72 h Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs 211234
Click to View More Cell Line Experimental Data

Biological Activity

Description Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
In vitro
In vitro Ribavirin significantly reduces the efficiency with which progeny subgenomic replicons transfect new cells in the replicon system, although ribavirin has little effect on levels of HCV replication. Ribavirin increases the mutation frequency of HCV, with the highest rates of mutations being found in the NS5A-encoding region. Ribavirin enhances TH1 while inhibiting T 2 cytokine production by stimulated T cells. [1] Ribavirin shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. Ribavirin reduces infectious poliovirus production to as little as 0. 00001% in cell culture. [2] Ribavirin's antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. [3] Ribavirin markedly reduces viral-induced parameters of macrophage activation at physiologic concentrations (up to 500 mg/mL). Ribavirin inhibits the production of IL-4 by Th2 cells, whereas it does not diminish the production of IFN-gamma in Th1 cells. [4] Ribavirin exhibits antiviral activity against a broad range of both DNA and RNA viruses in vitro. Ribavirin is a cytostatic agent and causes a reduction in synthesis of DNA, RNA and proteins in exposed cells. Ribavirin is thought to induce a switch in T-helper cell phenotype from type 2 to type 1. [5]
Experimental Result Images Methods Biomarkers Images PMID
Western blot p-AKT / AKT / pBP1 / BP1 Cyclin D1 EZH2 / p-ERK / ERK / p-eIF4E / eIF4E / p21 p53 / p-p53 / p21 / Mdm2 21415224
Growth inhibition assay Cell number 21415224
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05940545 Recruiting
CCHF
Liverpool School of Tropical Medicine
July 12 2023 Phase 1|Phase 2
NCT04283513 Not yet recruiting
Hemorrhagic Fever
U.S. Army Medical Research and Development Command
October 31 2022 Phase 2
NCT04335123 Completed
COVID-19
University of Kansas Medical Center
April 4 2020 Phase 1
NCT04285034 Completed
Lassa Fever
University of Oxford
November 26 2019 --
NCT03889106 Terminated
Lassa Fever
University of Oxford|National Institute for Health Research United Kingdom|Kenema Government Hospital|London School of Hygiene and Tropical Medicine|Public Health England
March 1 2019 --
NCT03585725 Terminated
Follicular Lymphoma|Mantle Cell Lymphoma
Weill Medical College of Cornell University|Memorial Sloan Kettering Cancer Center
September 26 2018 Early Phase 1

Chemical Information & Solubility

Molecular Weight 244.20864 Formula

C8H12N4O5

CAS No. 36791-04-5 SDF Download Ribavirin (ICN-1229) SDF
Smiles C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 49 mg/mL ( (200.64 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 49 mg/mL

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ribavirin (ICN-1229) | Ribavirin (ICN-1229) ic50 | Ribavirin (ICN-1229) price | Ribavirin (ICN-1229) cost | Ribavirin (ICN-1229) solubility dmso | Ribavirin (ICN-1229) purchase | Ribavirin (ICN-1229) manufacturer | Ribavirin (ICN-1229) research buy | Ribavirin (ICN-1229) order | Ribavirin (ICN-1229) mouse | Ribavirin (ICN-1229) chemical structure | Ribavirin (ICN-1229) mw | Ribavirin (ICN-1229) molecular weight | Ribavirin (ICN-1229) datasheet | Ribavirin (ICN-1229) supplier | Ribavirin (ICN-1229) in vitro | Ribavirin (ICN-1229) cell line | Ribavirin (ICN-1229) concentration | Ribavirin (ICN-1229) nmr